Prelude Therapeutics is a privately held biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases.
Location: United States, Delaware, Wilmington
Total raised: $110M
Investors 2
| Date | Name | Website |
| - | The Innova... | innovation... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.08.2020 | Series C | $50M | - |
| 12.06.2019 | Series B | $60M | - |
Mentions in press and media 9
| Date | Title | Description | Source |
| 05.03.2024 | Prelude Announces Acceptance of Multiple Preclinical Abstrac... | - | globenewsw... |
| 01.08.2023 | JLL to lease Delaware's Innovation Space | WILMINGTON, Del .- JLL has entered an exclusive arrangement with The Innovation Space™ to match tena... | us.jll.com... |
| 11.05.2021 | PRELUDE THERAPEUTICS INCORPORATED Prelude Therapeutics Anno... | - Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Ph... | marketscre... |
| 25.08.2020 | Prelude Therapeutics just raised a $50M Series C | In 2019, Prelude Therapeutics, the Wilmington-based biopharmaceutical oncology company, landed $60 m... | technical.... |
| 24.08.2020 | Prelude Therapeutics Announces Closing of $50M Series C Fina... | - | orbimed.co... |
| 24.08.2020 | Prelude Therapeutics Closes $50M in Series C | WILMINGTON, DE, Prelude Therapeutics announced that it has completed a $50M Series C financing rou... | vcnewsdail... |
| 12.06.2019 | Prelude Therapeutics Raises $60M in Series B Funding | Prelude Therapeutics, a Wilmington, Del.-based clinical-stage biopharmaceutical company, secured $60... | finsmes.co... |
| 12.06.2019 | Prelude Therapeutics nabs $60M series B, gains biopharma vet... | Prelude Therapeutics has completed a $60 million series B round, boosting its total raised to $95 mi... | fiercebiot... |
| - | Prelude Therapeutics raises $60M in Series B round for solid... | A company developing small-molecule targeted therapies for treating cancers has raised its latest ro... | medcitynew... |